RORY B RIGGS
CIK 1016835 · Chief Executive Officer · last filed 2026-06-04
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$40.61M
Companies
4
Total Filings
119
Lifetime Open-Market Net
-$221.94M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CBUS | Director | 14,940,447 | $1.23 | $18.38M | $5.47M | 12 | 2026-06-04 |
| Intra-Cellular Therapies, Inc. (ITCI) Delisted | Director | 0 | $131.87 | $0 | -$12.95M | 64 | 2025-04-02 |
| RPRX | Director | 405,286 | $54.87 | $22.24M | -$208.34M | 27 | 2024-02-22 |
| KYNTRA BIO, INC. (FGEN) Delisted | Director | 1,001,463 | $9.75 | $9.76M | -$6.13M | 15 | 2021-05-28 |
Recent Filings · Page 4 of 12
119 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2023-06-02 | — | Mixed | +4,042,548 | $31.5K | |
| 2023-05-22 | RPRX | Sell (S) | −1,750,000 | -$57.44M | EDGAR |
| 2023-05-12 | RPRX | Conv (C) | +300,000 | $0 | EDGAR |
| 2023-04-04 | Intra-Cellular Therapies, Inc. (ITCI) Delisted | Grant (A) | +313 | $16.9K | EDGAR |
| 2023-03-30 | RPRX | Sell (S) | −139,950 | -$5.08M | EDGAR |
| 2023-02-17 | RPRX | Conv (C) | +1,500,000 | $0 | EDGAR |
| 2023-01-03 | Intra-Cellular Therapies, Inc. (ITCI) Delisted | Grant (A) | +321 | $17.0K | EDGAR |
| 2022-12-13 | RPRX | Sell (S) | −60,000 | -$2.52M | EDGAR |
| 2022-11-21 | RPRX | Sell (S) | −120,000 | -$5.08M | EDGAR |
| 2022-10-04 | Intra-Cellular Therapies, Inc. (ITCI) Delisted | Grant (A) | +365 | $17.0K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.